MX2021001943A - Colecciones de péptidos, agentes peptídicos y métodos de uso de los mismos. - Google Patents

Colecciones de péptidos, agentes peptídicos y métodos de uso de los mismos.

Info

Publication number
MX2021001943A
MX2021001943A MX2021001943A MX2021001943A MX2021001943A MX 2021001943 A MX2021001943 A MX 2021001943A MX 2021001943 A MX2021001943 A MX 2021001943A MX 2021001943 A MX2021001943 A MX 2021001943A MX 2021001943 A MX2021001943 A MX 2021001943A
Authority
MX
Mexico
Prior art keywords
peptides
collections
methods
peptide agents
amino acid
Prior art date
Application number
MX2021001943A
Other languages
English (en)
Spanish (es)
Inventor
Gregory L Verdine
Mark Joseph Mulvihill
John Hanney Mcgee
Ty Matthew Thomson
Sebastian Christof Theodor Wahl
Araghi Raheleh Rezaei
Yue-Mei Zhang
Original Assignee
Fog Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fog Pharmaceuticals Inc filed Critical Fog Pharmaceuticals Inc
Publication of MX2021001943A publication Critical patent/MX2021001943A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
MX2021001943A 2018-08-20 2019-08-20 Colecciones de péptidos, agentes peptídicos y métodos de uso de los mismos. MX2021001943A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862719996P 2018-08-20 2018-08-20
PCT/US2019/047206 WO2020041270A1 (en) 2018-08-20 2019-08-20 Collections of peptides, peptide agents, and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2021001943A true MX2021001943A (es) 2021-07-15

Family

ID=69591277

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001943A MX2021001943A (es) 2018-08-20 2019-08-20 Colecciones de péptidos, agentes peptídicos y métodos de uso de los mismos.

Country Status (14)

Country Link
US (1) US12398178B2 (enExample)
EP (1) EP3840766A4 (enExample)
JP (1) JP2021535108A (enExample)
KR (1) KR20210060482A (enExample)
CN (1) CN113039195A (enExample)
AU (1) AU2019326423A1 (enExample)
BR (1) BR112021003113A2 (enExample)
CA (1) CA3110082A1 (enExample)
EA (1) EA202190531A1 (enExample)
IL (1) IL280931A (enExample)
MA (1) MA53446A (enExample)
MX (1) MX2021001943A (enExample)
SG (1) SG11202101672YA (enExample)
WO (1) WO2020041270A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020004555A2 (pt) * 2017-09-07 2020-09-24 Fog Pharmaceuticals, Inc. agentes que modulam funções de beta-catenina e métodos dos mesmos
AU2019326423A1 (en) 2018-08-20 2021-04-08 Fog Pharmaceuticals, Inc. Collections of peptides, peptide agents, and methods of use thereof
GB201909103D0 (en) * 2019-06-25 2019-08-07 Univ Bath Compounds
BR112023025528A2 (pt) * 2021-06-08 2024-02-27 Fog Pharmaceuticals Inc Peptídeos grampeados e métodos destes

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1680443B9 (en) 2003-11-05 2014-09-03 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
JP2010510236A (ja) 2006-11-15 2010-04-02 ダナ−ファーバー キャンサー インスティテュート インク． 安定化させたｍａｍｌペプチドおよびその使用法
CA2686827C (en) 2006-12-14 2014-09-16 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
US10716828B2 (en) 2007-05-02 2020-07-21 Dana-Farber Cancer Institute, Inc. Methods of modulating cellular homeostatic pathways and cellular survival
EP2208061B1 (en) 2007-09-26 2017-11-08 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
JP5788178B2 (ja) 2008-01-23 2015-09-30 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ウィルス感染症の治療のための組成物及び方法
EP2356139A4 (en) 2008-07-23 2013-01-09 Harvard College LIGURE COMBINED POLYPEPTIDES
EP3401684B1 (en) 2008-10-10 2022-03-16 Dana Farber Cancer Institute, Inc. Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides
EP3549951A3 (en) 2008-12-09 2019-11-20 Dana Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
EP3698811A1 (en) 2009-06-18 2020-08-26 Dana Farber Cancer Institute, Inc. Structured viral peptide compositions and methods of use
WO2011008260A2 (en) 2009-07-13 2011-01-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
US20130035304A1 (en) 2010-01-29 2013-02-07 Walensky Loren D Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
AU2011274474B2 (en) 2010-07-09 2015-06-18 Dana-Farber Cancer Institute, Inc. Stabilized insulinotropic peptides and methods of use
WO2012040459A2 (en) * 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
EP2637680B1 (en) 2010-11-12 2017-03-01 Dana-Farber Cancer Institute, Inc. Cancer therapies
CA2833171C (en) 2011-04-15 2021-08-31 Loren D. Walensky Targeting deregulated wnt signaling in cancer using stabilized alpha-helices of bcl-9
WO2012174423A1 (en) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Stabilized polypeptides as regulators of rab gtpase function
WO2012174409A1 (en) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Stabilized variant maml peptides and uses thereof
CA3173988A1 (en) 2011-10-11 2013-04-18 Dana-Farber Cancer Institute, Inc. Pyrazol-3-ones that activate pro-apoptotic bax
WO2013102211A2 (en) 2011-12-29 2013-07-04 Walensky Loren D Stabilized antiviral fusion helices
AU2013235425B2 (en) 2012-03-20 2017-09-21 Dana Farber Cancer Institute, Inc. Inhibition of MCL-1 and/or BFL-1/A1
CA3113959A1 (en) 2012-09-26 2014-04-03 President And Fellows Of Harvard College Proline-locked stapled peptides and uses thereof
WO2014055564A1 (en) 2012-10-01 2014-04-10 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
EP3782638A1 (en) 2013-03-13 2021-02-24 President and Fellows of Harvard College Stapled and stitched polypeptides and uses thereof
CA2906775A1 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Bh4 stabilized peptides and uses thereof
WO2014151369A2 (en) 2013-03-15 2014-09-25 Dana-Farber Cancer Institute, Inc. Stabilized ezh2 peptides
WO2014144148A1 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Stabilized sos1 peptides
WO2014197821A1 (en) 2013-06-06 2014-12-11 President And Fellows Of Harvard College Homeodomain fusion proteins and uses thereof
WO2014201370A1 (en) 2013-06-14 2014-12-18 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
US20160244494A1 (en) 2013-10-01 2016-08-25 President And Fellows Of Harvard College Stabilized polypeptides and uses thereof
US10039809B2 (en) 2013-12-18 2018-08-07 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
CN114805527A (zh) 2014-05-21 2022-07-29 哈佛大学的校长及成员们 Ras抑制肽和其用途
EP3270945A4 (en) 2015-03-18 2018-09-05 Massachusetts Institute of Technology Selective mcl-1 binding peptides
EP3310373A4 (en) 2015-06-22 2019-02-13 University of Utah Research Foundation Thiol-ene based peptide stapling and uses thereof
US10464975B2 (en) 2015-07-02 2019-11-05 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides
JP7049989B2 (ja) 2015-08-28 2022-04-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｂｆｌ－１と結合するペプチド
US20190002506A1 (en) 2015-08-28 2019-01-03 Dana-Farber Cancer Institute, Inc. Stabilized peptides for covalent binding to target protein
US10280317B2 (en) 2016-07-07 2019-05-07 Northwestern University Enhanced conductivity, adhesion and environmental stability of printed graphene inks with nitrocellulose
US11034720B2 (en) * 2016-07-17 2021-06-15 University Of Utah Research Foundation Thiol-yne based peptide stapling and uses thereof
BR112020004555A2 (pt) 2017-09-07 2020-09-24 Fog Pharmaceuticals, Inc. agentes que modulam funções de beta-catenina e métodos dos mesmos
AU2019326423A1 (en) 2018-08-20 2021-04-08 Fog Pharmaceuticals, Inc. Collections of peptides, peptide agents, and methods of use thereof
CA3159729A1 (en) 2019-12-11 2021-06-17 Amrita Singh CHANDHOKE Technologies useful for assessing permeability
EP4121082A4 (en) 2020-03-17 2024-05-01 Fog Pharmaceuticals, Inc. HELICALLY STAPLED PEPTIDES AND USES THEREOF
CA3186681A1 (en) 2020-07-22 2022-01-27 Brian Halbert WHITE Stapled peptides and methods thereof
CN116113621A (zh) 2020-07-22 2023-05-12 弗格制药有限公司 氨基酸
BR112023025528A2 (pt) 2021-06-08 2024-02-27 Fog Pharmaceuticals Inc Peptídeos grampeados e métodos destes
US20240376151A1 (en) 2022-10-31 2024-11-14 Fog Pharmaceuticals, Inc. Stapled peptides and methods thereof
US20260207704A1 (en) 2022-12-15 2026-07-23 Parabilis Medicines, Inc. Stapled peptides and methods thereof
WO2024130217A1 (en) 2022-12-15 2024-06-20 Fog Pharmaceuticals, Inc. Stapled peptides and methods thereof

Also Published As

Publication number Publication date
EA202190531A1 (ru) 2021-08-09
KR20210060482A (ko) 2021-05-26
SG11202101672YA (en) 2021-03-30
US12398178B2 (en) 2025-08-26
BR112021003113A2 (pt) 2021-05-11
US20210179665A1 (en) 2021-06-17
WO2020041270A1 (en) 2020-02-27
EP3840766A1 (en) 2021-06-30
EP3840766A4 (en) 2022-06-22
WO2020041270A9 (en) 2020-05-07
IL280931A (en) 2021-04-29
JP2021535108A (ja) 2021-12-16
CA3110082A1 (en) 2020-02-27
CN113039195A (zh) 2021-06-25
AU2019326423A1 (en) 2021-04-08
MA53446A (fr) 2021-06-30

Similar Documents

Publication Publication Date Title
CL2021000909A1 (es) Anticuerpos estabilizadores de trem2
EA202090090A1 (ru) Включение неприродных нуклеотидов и способы с ними
MX2020004578A (es) Composiciones de casz y metodos de uso.
CO2019003809A2 (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso
MX2022011309A (es) Receptores de celulas t.
MX2022006759A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
AR076977A1 (es) Proteinas precursoras repetitivas autoensambladas
CL2018000124A1 (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer
CL2019000119A1 (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123.
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
MX2017004559A (es) Receptores de celulas t.
ECSP13013102A (es) Dominios no inmunizados que se unen al suero y su uso para extender la vida media en el suero
CO6351750A2 (es) Composiciones y métodos para anticuerpos que se dirigen a la proteina de complementos c5
PE20181923A1 (es) Neoantigenos y metodos de su uso
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
UY36536A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
MX2016008958A (es) Proteinas quimericas de factor viii y usos de estas.
AR080914A1 (es) Proteinas de union al beta-amiloide
MX2015000397A (es) Complejo del factor viii con xten y proteina del factor von willebrand, y sus usos.
CO2023015915A2 (es) Anticuerpos anti-ccr8
BR112014027239A2 (pt) peptídeo, método de identificação de peptídeos, método para o tratamento de câncer, nucleotídeo, vetor, uso de um peptídeo e invenção
EA201491643A1 (ru) Идентификация мутаций канал-опсина-2 (chop2) и способы применения
WO2017025179A8 (en) A transglutamine tag for efficient site-specific bioconjugation
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
MX2023014679A (es) Peptidos grapados y metodos para su obtencion.